Public Health Emergency Medical Countermeasures Enterprise
Overview
The Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) is an interagency U.S. government partnership that funds and coordinates the development, acquisition, and stockpiling of medical countermeasures, including vaccines, drugs, and diagnostics, to address public health emergencies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Visby Medical | Mar 2022 | Grant | Lead |
| Vaxxas | Oct 2022 | Grant | Co-investor |
| Spero Biopharma | Jul 2018 | Grant | Co-investor |
| Cytovale | Feb 2022 | Grant | Co-investor |
| Ark Biotech | Aug 2025 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Public Health Emergency Medical Countermeasures Enterprise based?
Public Health Emergency Medical Countermeasures Enterprise is headquartered in Washington D.C., United States.
When was Public Health Emergency Medical Countermeasures Enterprise founded?
Public Health Emergency Medical Countermeasures Enterprise was founded in 2006.
How many portfolio companies does Public Health Emergency Medical Countermeasures Enterprise have?
Public Health Emergency Medical Countermeasures Enterprise has 97 portfolio companies in Caplight's dataset.
What are some companies in Public Health Emergency Medical Countermeasures Enterprise's portfolio?
Portfolio companies visible on Caplight include Visby Medical, Vaxxas, Spero Biopharma, Cytovale, Ark Biotech.
What was Public Health Emergency Medical Countermeasures Enterprise's most recent investment shown here?
Public Health Emergency Medical Countermeasures Enterprise's most recent investment in this portfolio sample was in Ark Biotech in 2025.
What sectors does Public Health Emergency Medical Countermeasures Enterprise focus on?
Public Health Emergency Medical Countermeasures Enterprise focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Energy & Sustainability, Frontier & Industrial Tech, Healthcare & Life Sciences, Enterprise Software, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, Enterprise Software, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Enterprise Software, Healthcare & Life Sciences, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Consumer & Commerce, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Public Health Emergency Medical Countermeasures Enterprise focus on?
Public Health Emergency Medical Countermeasures Enterprise typically invests at the MultiStage stage.
What is Public Health Emergency Medical Countermeasures Enterprise's AUM?
Public Health Emergency Medical Countermeasures Enterprise's assets under management are estimated between $1.0B and $10.0B.